TY - JOUR
T1 - Predicting diabetes mellitus metabolic goals and chronic complications transitions—analysis based on natural language processing and machine learning models
AU - Colmenares-Mejia, Claudia C.
AU - García-Suaza, Andrés F.
AU - Rodríguez-Lesmes, Paul
AU - Lochmuller, Christian
AU - Atehortúa, Sara C.
AU - Camacho-Cogollo, J. E.
AU - Martínez, Juan P.
AU - Rincón, Juliana
AU - Céspedes, Yohan R.
AU - Morales-Mendoza, Esteban
AU - Isaza-Ruget, Mario A.
N1 - Publisher Copyright:
© 2025 Colmenares-Mejia et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2025/4
Y1 - 2025/4
N2 - Objective To estimate Diabetes mellitus (DM) progression at one and two years in terms of glycemic targets and development of complications. Research design and methods We analyzed a retrospective cohort of adult DM patients treated in a Health Maintenance Organization in Colombia, including those with at least one glycosylated hemoglobin (HbA1c) measurement in 2018, 2019, and 2020. We defined four disease transition stages based on metabolic goals according to HbA1c levels and complications: 1. Within HbA1c goals and without complications; 2. Outside goals and without complications, 3. Within goals, but with complications, and 4. Outside goals and with complications. We applied Natural Language Processing (NLP) techniques to extract relevant clinical information from Electronic Health Records. Machine learning (ML) models were used to predict patient progression. Results A total of 23,802 patients were included. Despite achieving initial glycemic control, more than 60% of patients who started within HbA1c targets and without complications developed chronic complications within two years. Our models, which achieved up to 80% accuracy and F1 scores above 74%, identified key predictors of disease progression. Adherence to dyslipidemia treatment guidelines significantly reduced the likelihood of HbA1c deterioration and complications, whereas non-adherence to pharmacological treatments increased the risk of complications. These findings suggest that HbA1c control alone is insufficient to prevent disease progression and that a more comprehensive management approach—including lipid control, kidney function monitoring, and improved adherence to clinical guidelines—is necessary. Conclusions Patient compliance with pharmacological treatments, professional adherence to clinical practice guidelines, and lifestyle interventions play a crucial role in diabetes progression. While our models provide strong predictive capabilities, improving data quality and integration remains essential for better forecasting and intervention strategies.
AB - Objective To estimate Diabetes mellitus (DM) progression at one and two years in terms of glycemic targets and development of complications. Research design and methods We analyzed a retrospective cohort of adult DM patients treated in a Health Maintenance Organization in Colombia, including those with at least one glycosylated hemoglobin (HbA1c) measurement in 2018, 2019, and 2020. We defined four disease transition stages based on metabolic goals according to HbA1c levels and complications: 1. Within HbA1c goals and without complications; 2. Outside goals and without complications, 3. Within goals, but with complications, and 4. Outside goals and with complications. We applied Natural Language Processing (NLP) techniques to extract relevant clinical information from Electronic Health Records. Machine learning (ML) models were used to predict patient progression. Results A total of 23,802 patients were included. Despite achieving initial glycemic control, more than 60% of patients who started within HbA1c targets and without complications developed chronic complications within two years. Our models, which achieved up to 80% accuracy and F1 scores above 74%, identified key predictors of disease progression. Adherence to dyslipidemia treatment guidelines significantly reduced the likelihood of HbA1c deterioration and complications, whereas non-adherence to pharmacological treatments increased the risk of complications. These findings suggest that HbA1c control alone is insufficient to prevent disease progression and that a more comprehensive management approach—including lipid control, kidney function monitoring, and improved adherence to clinical guidelines—is necessary. Conclusions Patient compliance with pharmacological treatments, professional adherence to clinical practice guidelines, and lifestyle interventions play a crucial role in diabetes progression. While our models provide strong predictive capabilities, improving data quality and integration remains essential for better forecasting and intervention strategies.
UR - http://www.scopus.com/inward/record.url?scp=105002796203&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=105002796203&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0321258
DO - 10.1371/journal.pone.0321258
M3 - Research Article
AN - SCOPUS:105002796203
SN - 1932-6203
VL - 20
JO - PLOS ONE
JF - PLOS ONE
IS - 4 April
M1 - e0321258
ER -